David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)

Eli Lil­ly touts sky­rock­et­ing Moun­jaro pre­scrip­tions even as it re­ports an over­all slump in 2022 rev­enue

Eli Lil­ly is bet­ting big on its type 2 di­a­betes drug Moun­jaro amid sky­rock­et­ing pre­scrip­tions since its launch.

The com­pa­ny ex­pects US net prices to con­tin­ue to in­crease as ac­cess is broad­ened and paid pre­scrip­tions for the drug al­so in­crease.

Pre­scrip­tions for Moun­jaro peaked at about 180,000 per week in De­cem­ber, far out­pac­ing its own es­tab­lished type 2 drug Trulic­i­ty, ac­cord­ing to Lil­ly da­ta re­port­ed in its earn­ings re­port on Thurs­day. While Moun­jaro on­ly brought in Q4 rev­enue of $279.2 mil­lion, it’s ex­pect­ed to quick­ly be­come a block­buster.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.